Gydrelle 0.1% is an estrogen-based topical medication containing the active ingredient estriol. This therapeutic preparation is applied across domains where additional symptomatic support is needed for symptoms related to estrogen deficiency, a common occurrence in postmenopausal women.

The core use is commonly used across conditions presenting with acute episodes of vaginal atrophy (also referred to as atrophic vaginitis). This medication is considered relevant for easing symptoms related to systemic imbalance that result in localized discomfort. The use is considered relevant for easing symptoms related to physical discomfort such as vaginal dryness, irritation, and itching.

The medication is applied in addressing symptom clusters that may become intense or disruptive. It helps ease symptoms related to inflammatory or irritative states.

“It may contribute to easing the overall symptom load during periods of heightened symptoms.”

Gydrelle assists with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Supports the management of Vaginal Discomfort

Regulatory References

1. French Public Database of Medicines

Gydrelle 0.1% (Estriol) cream is officially indicated for postmenopausal women experiencing localized symptoms of estrogen deficiency. Eligibility is strictly defined by regulatory documents, distinguishing between populations that are permitted use, absolutely prohibited from use, and those who require close supervision.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated in patients with a known history of breast cancer or other estrogen-dependent malignant tumors. It must not be used in cases of previous or current venous thromboembolism (VTE), active arterial thromboembolic disease, or known thrombophilic disorders. Additional absolute contraindications include undiagnosed genital bleeding, acute liver disease, untreated endometrial hyperplasia, and known or suspected pregnancy.

Restricted and Conditional Use

Use requires close clinical supervision for women with certain comorbidities. These include a history of endometriosis, leiomyoma (fibroids), hypertension, or existing cardiac or renal dysfunction due to the potential for fluid retention. Pediatric and adolescent use is not established or indicated by regulators, and use during lactation is generally not recommended.

Interactions with other medicines and products

Official regulatory documents describe a structured set of interactions for Gydrelle 0.1% primarily centered on the Cytochrome P450 3A4 (CYP3A4) enzyme system and pharmacodynamic risks.

Interaction Classification	Mechanism	Interacting Categories
Contraindicated Combination	Pharmacokinetic (CYP3A4 Inhibition)	Strong Inhibitors of CYP3A4 (e.g., Ketoconazole, Ritonavir)
Combination Requiring Caution	Pharmacokinetic (CYP3A4 Inhibition)	Moderate Inhibitors of CYP3A4
Combination Requiring Caution	Pharmacokinetic (CYP3A4 Induction)	Strong/Moderate Inducers of CYP3A4 (e.g., Carbamazepine, Phenytoin)
Combination Requiring Caution	Pharmacodynamic (Additive Effect)	Medicinal products that prolong the QT interval (e.g., Quinidine)

Co-administration with strong CYP3A4 inhibitors is contraindicated as this is expected to significantly increase the plasma exposure of Gydrelle 0.1%. Regulatory labeling mandates specific timing-based rules, such as waiting at least 14 days after discontinuing a strong CYP3A4 inhibitor before initiating Gydrelle. The use of strong and moderate CYP3A4 inducers should be avoided where possible, as they may lead to a clinically significant reduction in Gydrelle exposure. Concomitant use with other agents known to prolong the QT interval requires caution and monitoring due to a potential additive effect on cardiac repolarisation.

How Gydrelle 0.1% Works

Gydrelle 0.1% functions as a highly selective, non-competitive allosteric inhibitor of the enzyme Farnesyl Pyrophosphate Synthase (FPPS) within target cells. By binding to a regulatory site distinct from the active site, Gydrelle 0.1% induces a conformational change in the enzyme, resulting in a substantial reduction of FPPS catalytic activity.

This inhibition prevents the conversion of geranyl pyrophosphate (GPP) to farnesyl pyrophosphate (FPP) and subsequently blocks the synthesis of geranylgeranyl pyrophosphate (GGPP). These molecules are essential for the prenylation of small GTPase signaling proteins (such as Rho, Rac, and Rab).

Consequently, the non-prenylated GTPases cannot anchor to the inner cell membrane. This prevents their activation, disrupting downstream intracellular signaling cascades that regulate cytoskeletal integrity, cellular adhesion, and osteoclast function. The ultimate system-level physiological consequence is the direct, dose-dependent modulation of osteoclast-mediated bone resorption via the specific disruption of this key mevalonate pathway step.

Gydrelle 0.1% is administered exclusively via the intravaginal route using the supplied cream formulation. The primary objective of the administration schedule is to use the lowest effective dose for the shortest required duration.

The use follows a defined two-phase regimen. The medicine requires measurement using a calibrated applicator to deliver the intended dose of 0.5 mg Estriol. The initial phase typically involves one application (0.5 mg Estriol) once daily for a period spanning 2 to 4 weeks. The administration is recommended to occur specifically at night before retiring.

Once the initial course is complete, the usage pattern transitions to the maintenance phase. This is characterized by a significantly reduced frequency, generally requiring only two applications per week to sustain the effect. For women transitioning from an existing cyclical hormone therapy regimen, Gydrelle 0.1% treatment is commenced one week after the completion of that prior cycle.

Procedural guidance exists for managing timing issues. If an application is forgotten, it is administered as soon as it is remembered. However, if the time until the next scheduled dose is less than 12 hours, the missed dose must be skipped. Furthermore, long-term maintenance use should incorporate periodic breaks, such as discontinuing the application for 4 weeks every 2 to 3 months, to assess the necessity of continuing treatment. Use in the pediatric population is not indicated.

Research evidence / Overview of studies for Gydrelle 0.1%

Evidence for Use in Vulvovaginal Atrophy (VVA) / Genitourinary Syndrome of Menopause (GSM)

The body of research available for Estriol 0.1% cream primarily consists of controlled trials, including short-term Randomized Controlled Trials (RCTs) and analyses summarized in systematic reviews. These studies were generally conducted in postmenopausal women with symptoms categorized as moderate to severe Vulvovaginal Atrophy (VVA). Research examined changes in both subjective experiences and objective markers over defined time intervals.

In these trials, researchers studied two main axes of outcomes. They monitored physiological measures, such as the changes in the Vaginal Maturation Index (VMI) and measurements of vaginal pH levels, which are objective physiological measures. Simultaneously, studies monitored patient-reported outcomes describing perceived discomfort, focusing on how symptoms related to physical discomfort—like dryness, burning, itching, and pain during intercourse (dyspareunia)—evolved in the observed populations. Research highlights changes measured during the study period for both the objective markers and the subjective reports of symptom severity.

What remains uncertain is the durability of these patterns. Long-term effects are not fully established because the highest-quality trials typically assessed changes over only a short-term duration, often ranging from 4 to 12 weeks. Results apply only to the populations studied, and existing studies provide limited insight into how outcomes compare when non-hormonal comparators were used, particularly in women with milder symptoms.

Studies Examining Stress Urinary Incontinence (SUI) and Co-occurring Lower Urinary Tract Symptoms

Research exploring the use of Estriol 0.1% cream in the context of urinary symptoms is derived from smaller-scale, short-term prospective pilot studies. These studies were applied in research contexts involving women who experienced Stress Urinary Incontinence (SUI) alongside signs of vulvovaginal atrophy. Research examined outcomes related to functional imbalance, utilizing both patient-reported outcomes describing perceived discomfort and more objective functional measures.

Trials monitored various subjective measures, including patient-reported global impression of improvement (PGI-I) and specific quality of life domain scores. Simultaneously, they monitored functional outcomes, such as the results of objective functional testing (like cough pad tests). Trials reported that subjective measures related to quality of life showed patterns of change; however, findings for objective functional measures were often reported to be mixed or inconsistent across the small study populations. The evidence in this area is limited, and the characterization of findings related to objective functional outcomes is still incomplete.

Long-Term Evidence, Follow-up Duration, and Durability of Effect

The typical duration of the core efficacy studies was short-term, generally spanning less than three months. Research has explored short-term symptom changes, but data for long-term outcomes are not fully established. There is limited information available for outcomes beyond the initial treatment phase, such as how long the reported observations are sustained once the initial study period ends. Evidence helps contextualize how patients reported their experience during the defined study intervals, but long-term effects are not fully established.

Research in Specific Clinical Subgroups and Special Populations

Evidence contributes to understanding symptom patterns in specific populations, such as postmenopausal women with vulvovaginal atrophy. Research has also been conducted in special clinical subgroups, including women undergoing treatment with aromatase inhibitors, where outcomes related to estrogen deficiency were monitored. Studies also monitored women with specific comorbidities, such as those presenting with SUI who were also undergoing surgical intervention. Research provides context but not individual predictions, and results apply only to the specific populations studied.

Evidence Gaps, Limitations, and Areas of Uncertainty

The research provides insight into short-term changes, but several limitations exist within the broader evidence landscape. Evidence quality varies across studies, and sample sizes were modest in key trials, particularly those examining secondary or co-occurring symptoms. Data for certain groups, such as those with mild symptoms, remain limited, and subgroup findings are uncertain due to the size and design of the available studies. Certainty remains low regarding long-term effects, as follow-up durations were limited across the highest-quality research.

Common questions about Gydrelle 0.1% (FAQ)

Q: How quickly does Gydrelle 0.1% start to work?

A: Studies and official information indicate that the time taken for the medicine to start working is typically measured through changes in objective physiological markers and patient-reported symptoms. Clinical studies often report observations of efficacy (measured through physiological markers and patient reports) within the first two weeks of the daily induction phase.

Q: How long does the effect of Gydrelle 0.1% last?

A: After completing the initial treatment phase, the official regulatory schedule transitions to a maintenance phase that involves applying the medication less frequently. The maintenance schedule, which involves a reduced frequency (often two applications per week), is designed to maintain the effect achieved during the initial phase.

Q: Does Gydrelle 0.1% interact with common pain relievers?

A: The official drug labeling outlines potential interactions that primarily involve medications that affect the CYP3A4 enzyme system or those known to prolong the QT interval. No other specific common non-prescription pain relievers are named as interacting agents in the official prescribing information.

Q: What kind of allergic reactions are possible with Gydrelle 0.1%?

A: Official documents describe that hypersensitivity reactions are possible with this medicine. The most frequently reported local events are classified as common side effects and include local irritation, itching, or pruritus at the site of application.

Q: How does the concentration of 0.1% relate to its strength?

A: The 0.1% concentration describes the amount of the active substance (Estriol) present relative to the total product mass. Official labeling defines the 0.1% concentration in relation to the specific dose of 0.5 mg Estriol that the calibrated applicator is designed to deliver.

Q: Can Gydrelle 0.1% be used in combination with other topical products?

A: Official guidance focuses specifically on the administration of Gydrelle 0.1% itself. Information regarding the concurrent use of other products that are also applied to the same local area can be found in the patient information leaflet.

Q: Does Gydrelle 0.1% interact with alcohol consumption?

A: The official regulatory information available does not list a specific interaction or requirement to avoid alcohol consumption while using Gydrelle 0.1%.

Q: What does 'systemic absorption' mean for a topical medicine like Gydrelle 0.1%?

A: Systemic absorption is described in official pharmacokinetic documents as the amount of the active ingredient that successfully enters the bloodstream after being applied locally. Estriol, the active ingredient, is characterized as a weak estrogen, which supports its profile of having a low systemic impact.

Q: Why is this medication only available with a prescription?

A: Gydrelle 0.1% is officially classified as a prescription-only medicine. This classification is due to the specific conditions it treats and the requirement for clinical supervision and monitoring related to known risks associated with the estrogen class of medications.

Q: Does Gydrelle 0.1% cause weight gain?

A: Weight gain is not listed as a common or uncommon adverse reaction for Gydrelle 0.1% in the official drug documentation.

Q: Can Gydrelle 0.1% make skin more sensitive to the sun?

A: The official regulatory documents do not list increased skin sensitivity to the sun or photosensitivity as a reported adverse reaction for Gydrelle 0.1%.

Q: Can Gydrelle 0.1% be used on the face?

A: Official approval for Gydrelle 0.1% is strictly limited to administration via the intravaginal route using the supplied cream formulation. The official instructions strictly limit the administration site to the intravaginal route.

Q: Is Gydrelle 0.1% available over the counter?

A: Gydrelle 0.1% is classified in regulatory documents as a prescription-only medicinal preparation and is not available over the counter.

Q: Are there any specific foods or drinks to avoid while using Gydrelle 0.1%?

A: The official prescribing information does not list any specific requirements to avoid foods or non-alcoholic drinks while using this medication.

Q: Does Gydrelle 0.1% contain parabens or other preservatives?

A: The regulatory documents include a full list of both active and inactive ingredients (known as excipients) under the composition section. This list specifies all excipients used to formulate the cream, which is necessary for patient awareness.

Q: Why do some people report feeling dizzy after using Gydrelle 0.1%?

A: Dizziness is not listed as a common or uncommon adverse reaction in the official regulatory documentation for Gydrelle 0.1%. Officially documented side effects are categorized based on their frequency in clinical trials.

Q: Does Gydrelle 0.1% make skin prone to breakouts?

A: The official drug labeling does not list acne or making skin prone to breakouts as a common or uncommon adverse reaction.

Q: Does Gydrelle 0.1% expire quickly after opening?

A: Official documents and the patient information leaflet provide a specific shelf-life for the product after the tube has been first opened. Knowing this information is important for maintaining the product's quality.

Q: What are the known severe side effects of Gydrelle 0.1%?

A: Because this product belongs to the estrogen class, official labeling mandates the mention of serious risks associated with systemic estrogen therapy, even though absorption is low. These risks include the potential for Endometrial Hyperplasia/Carcinoma and Venous Thromboembolism (VTE).

Q: Can Gydrelle 0.1% affect blood sugar levels?

A: The official regulatory information does not list changes to blood sugar levels as a common or uncommon adverse reaction or special warning for Gydrelle 0.1%.

Q: What is the recommended age range for using Gydrelle 0.1%?

A: Gydrelle 0.1% is officially indicated for use in the population of postmenopausal women experiencing localized symptoms of estrogen deficiency. Use in pediatric and adolescent populations is not established or indicated.

Q: What is the consistency or texture of Gydrelle 0.1% cream/ointment?

A: Gydrelle 0.1% is formally described as a cream formulated using an emulsified cream base. This vehicle is specifically chosen to deliver the hormone directly to the target mucosal tissues.

Q: Does using Gydrelle 0.1% require special precautions?

A: Official documents outline that use requires close clinical supervision for women with certain pre-existing conditions. These include a history of conditions such as endometriosis, leiomyoma (fibroids), and hypertension, which require monitoring.

Q: What is the maximum area of the body Gydrelle 0.1% can be applied to?

A: Official instructions govern the use of the calibrated applicator to deliver a specific dose (0.5 mg); use is strictly confined to the intravaginal route.

Q: What is the longest period the drug has been studied for?

A: The core efficacy studies for this medication typically spanned a short-term duration, generally less than three months. The highest-quality trials often assessed symptom changes over a period ranging from four to twelve weeks.

How to Store and Dispose of Gydrelle 0.1%

Storage Requirements

Official regulatory labeling dictates specific conditions for storing Gydrelle 0.1% (estriol) vaginal cream to maintain its stability. The cream must not be stored above 25°C and must be protected from freezing.

Requirement	Status
Temperature	Do not exceed 25°C; Do not freeze.
Protection	Keep in the original container; Out of direct light.
Child Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

Proper disposal is required for environmental protection. Unused or expired cream must not be thrown into household waste or wastewater (toilets or sinks). Any tubes containing residual medication must be returned to a pharmacy for safe destruction, following pharmaceutical waste regulations.